Blood pressure after PREeclampsia/HELLP by SELF monitoring (BP-PRESELF): rationale and design of a multicenter randomized controlled trial

Hella E C Muijsers, Olivier W H van der Heijden, Karin de Boer, Chantal van Bijsterveldt, Ciska Buijs, Jens Pagels, Peter Tönnies, Susanne Heiden, Nel Roeleveld, Angela H E M Maas, Hella E C Muijsers, Olivier W H van der Heijden, Karin de Boer, Chantal van Bijsterveldt, Ciska Buijs, Jens Pagels, Peter Tönnies, Susanne Heiden, Nel Roeleveld, Angela H E M Maas

Abstract

Background: Hypertensive disorders of pregnancy (HDP), such as preeclampsia (PE) or the Hemolysis Elevated Liver enzymes and Low Platelets (HELLP) syndrome are associated with elevated cardiovascular disease (CVD) risks, but standardized prevention guidelines after such pregnancies are lacking. Hypertension is the first emerging risk factor after PE/HELLP pregnancies and is a major risk factor for CVD. Hypertension before the age of 55 years may lead to various manifestations of end-organ damage at relatively young age. Therefore, timely treatment of elevated blood pressure is mandatory, but many of these high-risk women have long-term undetected and untreated hypertension before adequate treatment is initiated.

Aim: The aim of our study is to assess whether home blood pressure monitoring (HBPM) in women with a previous PE/HELLP pregnancy is a valuable tool for the early detection of hypertension.

Methods: Women with a history of both early and late PE/HELLP syndrome aged 40-60 years are invited to participate. Patients with a history of CVD, known hypertension and/or use of antihypertensive medication are excluded. Women are randomized between HPBM or 'usual care'. The primary outcome is feasibility and usability of HBPM after 1 year of follow-up. Secondary outcomes will be the effectiveness of HPBM to detect hypertension, the efficacy of BP treatment, quality of life, health-related symptoms, work ability, and life-style behaviour. The results of this study will provide better strategies for timely detection and prevention of hypertension in women after PE/HELLP.

Trial registration: ClinicalTrials.gov, NCT03228082. Registered June 15, 2017.

Keywords: Cardiovascular disease; Cardiovascular risk factor; Home blood pressure monitoring; Hypertension; Preeclampsia; eHealth.

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2224–2260. doi: 10.1016/S0140-6736(12)61766-8.
    1. Patel SA, Winkel M, Ali MK, Narayan KM, Mehta NK. Cardiovascular mortality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data. Ann Intern Med. 2015;163(4):245–253. doi: 10.7326/M14-1753.
    1. Heida KY, Bots ML, de Groot CJ, van Dunne FM, Hammoud NM, Hoek A, et al. Cardiovascular risk management after reproductive and pregnancy-related disorders: a Dutch multidisciplinary evidence-based guideline. Eur J Prev Cardiol. 2016;23(17):1863–1879. doi: 10.1177/2047487316659573.
    1. Stuart JJ, Tanz LJ, Cook NR, Spiegelman D, Missmer SA, Rimm EB, et al. Hypertensive disorders of pregnancy and 10-year cardiovascular risk prediction. J Am Coll Cardiol. 2018;72(11):1252–1263. doi: 10.1016/j.jacc.2018.05.077.
    1. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur Heart J. 2016;37(29):2315–2381. doi: 10.1093/eurheartj/ehw106.
    1. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J. 2008;156(5):918–930. doi: 10.1016/j.ahj.2008.06.042.
    1. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol. 2013;28(1):1–19. doi: 10.1007/s10654-013-9762-6.
    1. Mannisto T, Mendola P, Vaarasmaki M, Jarvelin MR, Hartikainen AL, Pouta A, et al. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation. 2013;127(6):681–690. doi: 10.1161/CIRCULATIONAHA.112.128751.
    1. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97–104. doi: 10.1016/j.preghy.2014.02.001.
    1. Schutte J, Steegers E, Schuitemaker N, Santema J, de Boer K, Pel M, et al. Rise in maternal mortality in the Netherlands. BJOG. 2010;117(4):399–406. doi: 10.1111/j.1471-0528.2009.02382.x.
    1. Steegers EAP, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631–644. doi: 10.1016/S0140-6736(10)60279-6.
    1. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180(2 Pt 1):499–506. doi: 10.1016/S0002-9378(99)70239-5.
    1. Harmon AC, Cornelius DC, Amaral LM, Faulkner JL, Cunningham MW, Jr, Wallace K, et al. The role of inflammation in the pathology of preeclampsia. Clin Sci (Lond) 2016;130(6):409–419. doi: 10.1042/CS20150702.
    1. Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta. 2009;30(Suppl A):S38–S42. doi: 10.1016/j.placenta.2008.11.021.
    1. Kalafat E, Thilaganathan B. Cardiovascular origins of preeclampsia. Curr Opin Obstet Gynecol. 2017;29(6):383–389. doi: 10.1097/GCO.0000000000000419.
    1. Perry H, Khalil A, Thilaganathan B. Preeclampsia and the cardiovascular system: an update. Trends Cardiovasc Med. 2018.
    1. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA. 2001;285(12):1607–12. doi: 10.1001/jama.285.12.1607.
    1. Yinon Y, Kingdom JC, Odutayo A, Moineddin R, Drewlo S, Lai V, et al. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation. 2010;122(18):1846–1853. doi: 10.1161/CIRCULATIONAHA.110.948455.
    1. Kvehaugen AS, Dechend R, Ramstad HB, Troisi R, Fugelseth D, Staff AC Endothelial function and circulating biomarkers are disturbed in women and children after preeclampsia. Hypertension. 2011;58(1):63–69. doi: 10.1161/HYPERTENSIONAHA.111.172387.
    1. Libby P, Nahrendorf M, Swirski FK. Leukocytes link local and systemic inflammation in ischemic cardiovascular disease: an expanded "cardiovascular continuum". J Am Coll Cardiol. 2016;67(9):1091–1103. doi: 10.1016/j.jacc.2015.12.048.
    1. Staff AC. Johnsen GM, Dechend R, Redman CWG. Preeclampsia and uteroplacental acute atherosis: immune and inflammatory factors. J Reprod Immunol. 2014;101–102:120–126. doi: 10.1016/j.jri.2013.09.001.
    1. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974. doi: 10.1136/.
    1. Drost JT, Arpaci G, Ottervanger JP, de Boer MJ, van Eyck J, van der Schouw YT, et al. Cardiovascular risk factors in women 10 years post early preeclampsia: the preeclampsia risk EValuation in FEMales study (PREVFEM) Eur J Prev Cardiol. 2012;19(5):1138–1144. doi: 10.1177/1741826711421079.
    1. Behrens I, Basit S, Melbye M, Lykke JA, Wohlfahrt J, Bundgaard H, et al. Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. BMJ. 2017;358:j3078. doi: 10.1136/bmj.j3078.
    1. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(5):1545–1588. doi: 10.1161/01.str.0000442009.06663.48.
    1. Haug EB, Horn J, Markovitz AR, Fraser A, Klykken B, Dalen H, et al. Association of Conventional Cardiovascular Risk Factors with Cardiovascular Disease after Hypertensive Disorders of pregnancy: analysis of the Nord-Trøndelag health study. JAMA Cardiol. 2019;4(7):628–635. doi: 10.1001/jamacardio.2019.1746.
    1. Lawes CMM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513–1518. doi: 10.1016/S0140-6736(08)60655-8.
    1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339.
    1. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, Evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71(6):e13–e115.
    1. Warren RE, Marshall T, Padfield PL, Chrubasik S. Variability of office, 24-hour ambulatory, and self-monitored blood pressure measurements. Br J Gen Pract. 2010;60(578):675–680. doi: 10.3399/bjgp10X515403.
    1. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens. 2010;24(12):779–785. doi: 10.1038/jhh.2010.54.
    1. Stergiou GS, Bliziotis IA. Home blood pressure monitoring in the diagnosis and treatment of hypertension: a systematic review. Am J Hypertens. 2011;24(2):123–134. doi: 10.1038/ajh.2010.194.
    1. Richards T., Montori V. M., Godlee F., Lapsley P., Paul D. Let the patient revolution begin. BMJ. 2013;346(may14 1):f2614–f2614. doi: 10.1136/bmj.f2614.
    1. McManus RJ, Mant J, Franssen M, Nickless A, Schwartz C, Hodgkinson J, et al. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet. 2018.
    1. BVC. Castor Electronic Data Capture. Amsterdam 2016.
    1. Pejtersen JH, Kristensen TS, Borg V, Bjorner JB. The second version of the Copenhagen Psychosocial Questionnaire. Scand J Public Health. 2010;38(3_suppl):8–24. doi: 10.1177/1403494809349858.
    1. van Veldhoven M, Broersen S. Measurement quality and validity of the "need for recovery scale". Occup Environ Med. 2003;60(Suppl 1):i3–i9. doi: 10.1136/oem.60.suppl_1.i3.
    1. van Veldhoven MJ, Sluiter JK. Work-related recovery opportunities: testing scale properties and validity in relation to health. Int Arch Occup Environ Health. 2009;82(9):1065–1075. doi: 10.1007/s00420-009-0411-z.
    1. Topouchian J, Agnoletti D, Blacher J, Youssef A, Chahine MN, Ibanez I, et al. Validation of four devices: Omron M6 comfort, Omron HEM-7420, Withings BP-800, and Polygreen KP-7670 for home blood pressure measurement according to the European Society of Hypertension International Protocol. Vasc Health Risk Manag. 2014;10:33–44.
    1. Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Groen SE, Kadrmas HM, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310(1):46–56. doi: 10.1001/jama.2013.6549.
    1. Verberk WJ, Kroon AA, Lenders JW, Kessels AG, van Montfrans GA, Smit AJ, et al. Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: a randomized, controlled trial. Hypertension. 2007;50(6):1019–1025. doi: 10.1161/HYPERTENSIONAHA.107.094193.
    1. McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet. 2010;376(9736):163–172. doi: 10.1016/S0140-6736(10)60964-6.
    1. McManus RJ, Mant J, Haque MS, Bray EP, Bryan S, Greenfield SM, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA. 2014;312(8):799–808. doi: 10.1001/jama.2014.10057.
    1. Cairns AE, Tucker KL, Leeson P, Mackillop LH, Santos M, Velardo C, et al. Self-Management of Postnatal Hypertension: the SNAP-HT trial. Hypertension. 2018;72(2):425–432. doi: 10.1161/HYPERTENSIONAHA.118.10911.
    1. McManus RJ, Bray EP, Mant J, Holder R, Greenfield S, Bryan S, et al. Protocol for a randomised controlled trial of telemonitoring and selfmanagement in the control of hypertension: telemonitoring and self-management in hypertension. [ISRCTN17585681]. BMC Cardiovasc Disord. 2009;9:6. 10.1186/1471-2261-9-6.
    1. Stergiou GS, Omboni S, Parati G. Home or ambulatory blood pressure monitoring for the diagnosis of hypertension? J Hypertens. 2015;33(8):1528–1530. doi: 10.1097/HJH.0000000000000677.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다